Aurobindo Pharma (AUROPHARMA) — Announcement

📢 Key Event
Aurobindo Pharma signs non-exclusive voluntary license agreement with MSD

💡 Investor Takeaway
This partnership enhances Aurobindo Pharma's global health footprint and may lead to future market access and revenue growth in emerging markets.

Aurobindo Pharma announced a non-exclusive voluntary license agreement with MSD to manufacture and supply generic alimatravir for HIV prevention across 129 low- and middle-income countries, pending regulatory approvals, marking a strategic expansion into global health partnerships and potential future revenue streams.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Limited (AUROPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹87,805.59 Cr P/E: 25.3

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"How will this agreement affect Aurobindo Pharma's revenue in the next fiscal year?" "What regulatory milestones must be met before supply begins in LMICs?" "How does this compare to similar licensing deals by other generic manufacturers?"

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 24 July 2026

CGPOWER CG Power and Industrial Solutions Limited Financial Results OMAXAUTO Omax Autos Limited Financial Results NITCO Nitco Limited Corporate Action LENSKART Lenskart Solutions Limited Annual Report ALLDIGI Alldigi Tech Limited Financial Results RKFORGE Ramkrishna Forgings Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.